CANbridge Pharmaceuticals Inc.
HKSE: 1228.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Qun Xue
- Employees
- 67
- Headquarters
- Beijing, China
- IPO year
- 2021
- Market cap
- HK$977.1M
- Website
- https://www.canbridgepharma.com
Loading 1228…
Loading profile data…Frequently asked questions about 1228
What does CANbridge Pharmaceuticals Inc. (1228.HK) do?
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase i...
Where does 1228.HK trade?
CANbridge Pharmaceuticals Inc. (1228.HK) trades on the Hong Kong Stock Exchange.
What sector is 1228.HK in?
CANbridge Pharmaceuticals Inc. (1228.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CANbridge Pharmaceuticals Inc.?
Qun Xue is the chief executive officer of CANbridge Pharmaceuticals Inc. (1228.HK).
Where is CANbridge Pharmaceuticals Inc. headquartered?
CANbridge Pharmaceuticals Inc. is headquartered in China.
Does 1228.HK pay a dividend?
CANbridge Pharmaceuticals Inc. (1228.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 1228.HK go public?
CANbridge Pharmaceuticals Inc. (1228.HK) completed its initial public offering in 2021.